Search Result

Results for "

chronic kidney disease (CKD)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (2) Biochemical Assay Reagents (3) Cannabinoid Receptor (2) CaSR (3) Cytochrome P450 (1) Drug Isomer (1) Drug Metabolite (1) Dynamin (1) E1/E2/E3 Enzyme (2) Endogenous Metabolite (1) Environmental Pollutants (1) Ferroportin (1) Guanylate Cyclase (2) Hepcidin (1) HIF/HIF Prolyl-Hydroxylase (3) HIV Integrase (1) Keap1-Nrf2 (2) NF-κB (2) NO Synthase (2) Procollagen C Proteinase (1) Reactive Oxygen Species (ROS) (3) Reference Standards (1) SARS-CoV (2) Sodium Phosphate Cotransporter (1) SphK (2) TGF-β Receptor (1) Thrombin (1) TRP Channel (3) VD/VDR (1) Virus Protease (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (9) Endocrinology (6) Infection (4) Inflammation/Immunology (12) Metabolic Disease (13) Neurological Disease (1)

By Targets:

Antibiotic (1)

Apoptosis (2)

Biochemical Assay Reagents (3)

Cannabinoid Receptor (2)

CaSR (3)

Cytochrome P450 (1)

Drug Isomer (1)

Drug Metabolite (1)

Dynamin (1)

E1/E2/E3 Enzyme (2)

Endogenous Metabolite (1)

Environmental Pollutants (1)

Ferroportin (1)

Guanylate Cyclase (2)

Hepcidin (1)

HIF/HIF Prolyl-Hydroxylase (3)

HIV Integrase (1)

Keap1-Nrf2 (2)

NF-κB (2)

NO Synthase (2)

Procollagen C Proteinase (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (1)

SARS-CoV (2)

Sodium Phosphate Cotransporter (1)

SphK (2)

TGF-β Receptor (1)

Thrombin (1)

TRP Channel (3)

VD/VDR (1)

Virus Protease (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (1)

Cardiovascular Disease (9)

Endocrinology (6)

Infection (4)

Inflammation/Immunology (12)

Metabolic Disease (13)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13324

Bardoxolone methyl Maximum Cited Publications 41 Publications Verification RTA 402; NSC 713200; CDDO Methyl ester	Keap1-Nrf2 SARS-CoV Virus Protease	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Bardoxolone (CDDO; RTA 401) methyl is an orally active and blood-brain-barrier-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC₅₀ value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD) .

HY-N1428C

Ferric citrate 5 Publications Verification Iron(III) citrate; Zerenex	Reactive Oxygen Species (ROS) Antibiotic	Metabolic Disease
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-12654

Molidustat 5+ Cited Publications BAY 85-3934	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-126397

MnTBAP chloride 5+ Cited Publications	NF-κB	Inflammation/Immunology
MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research .

HY-13102

UK-383367	Procollagen C Proteinase	Others
UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC₅₀ value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring .

HY-112671

CDDO-dhTFEA RTA dh404	Keap1-Nrf2 NF-κB Apoptosis	Cardiovascular Disease Inflammation/Immunology
CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .

HY-113493

4-Pyridoxic acid	Endogenous Metabolite	Metabolic Disease
4-Pyridoxic acid is an endogenous substrate of renal organic anion transporters (OAT1/3) and a catabolite of vitamin B6. 4-Pyridoxic acid is excreted through OAT1/3-mediated tubular active secretion, which can reflect OAT1/3 activity. Elevated plasma concentrations of 4-Pyridoxic acid are associated with decreased OAT1/3 activity in chronic kidney disease (CKD) and can be used as a biomarker to reflect the severity of knee osteoarthritis (KOA) and lumbar spondylosis (LS) .

HY-P11178

Corisin	Apoptosis SARS-CoV	Infection Metabolic Disease Inflammation/Immunology
Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF) .

HY-119572

Sodium zirconium cyclosilicate	Biochemical Assay Reagents	Inflammation/Immunology
Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K ⁺ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD) .

HY-123572

Bis-T-23 AG1717	Dynamin HIV Integrase	Infection Metabolic Disease Inflammation/Immunology
Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .

HY-109136

Runcaciguat 1 Publications Verification BAY 1101042	Guanylate Cyclase	Cardiovascular Disease Metabolic Disease
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .

HY-109106A

Upacicalcet sodium SK-1403; AJT240; PLS240	CaSR	Endocrinology
Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca ²⁺ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .

HY-W416250

p-Cresol glucuronide	Drug Metabolite	Cardiovascular Disease
p-Cresol glucuronide, a metabolite of p-cresol, is a prototype protein-bound uremic toxin. p-Cresol glucuronide is associated with chronic kidney disease (CKD) .

HY-47030

Ferric citrate hydrate	Environmental Pollutants Biochemical Assay Reagents	Metabolic Disease
Ferric citrate hydrate, an orally active iron supplement, is an efficacious phosphate binder. Ferric citrate hydrate can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-141411A

Zevaquenabant (S)-MRI-1867	Cannabinoid Receptor NO Synthase	Metabolic Disease
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .

HY-145150

TRPC5-IN-1 1 Publications Verification	TRP Channel	Metabolic Disease
TRPC5-IN-1 (Compound 6j) is a selective TRPC5 inhibitor with 50.5 % Inhibition for TRPC5 at 3 μM. TRPC5-IN-1 can be used for the research of chronic kidney disease (CKD) .

HY-120268A

SLM6031434 hydrochloride	SphK	Inflammation/Immunology
SLM6031434 hydrochloride is the hydrochloride salt form of SLM6031434 (HY-120268). SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC₅₀ value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .

HY-153092

Avenciguat BI-685509	Guanylate Cyclase	Cardiovascular Disease Metabolic Disease
Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .

HY-122052

UK‑396082	Thrombin	Metabolic Disease
UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD) .

HY-111314

NZ 419 5-Hydroxy-1-methylhydantoin	Reactive Oxygen Species (ROS)	Inflammation/Immunology
NZ 419 (5-Hydroxy-1-methylhydantoin) is a metabolite of creatinine and an antioxidant with oral activity, which has the ability to scavenge hydroxyl radicals (•OH). NZ 419 can inhibit the progression of chronic kidney disease (CKD) in rats .

HY-P6441

KP-6	β-catenin Wnt	Inflammation/Immunology
KP-6, a polypeptide, is a Wnt/β-catenin signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD) .

HY-175985

MPO-IN-9	Reactive Oxygen Species (ROS)	Inflammation/Immunology
MPO-IN-9 is a selective inhibitor of myeloperoxidase (MPO), with an IC₅₀ value of 3.9 nM. MPO-IN-9 inhibits MPO-mediated ROS production and protects NO-dependent vascular function by blocking MPO's chlorination and peroxidation cycles. MPO-IN-9 can be used for the study of diseases such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH) .

HY-120268

SLM6031434	SphK	Inflammation/Immunology
SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC₅₀ value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .

HY-109106

Upacicalcet SK-1403 free acid; AJT240 free acid; PLS240 free acid	CaSR	Endocrinology
Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-W747868

Molidustat sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .

HY-162584

TRPC5-IN-6	TRP Channel	Others
TRPC5-IN-6 (Compound 12) is an orally effective transient receptor potential (TRPC5) inhibitor with a IC₅₀ value of 81 nM. TRPC5-IN-6 has good biosafety and low liver and kidney toxicity, and is expected to play an important role in the treatment of chronic kidney disease (CKD) .

HY-144429

TRPC5-IN-4	TRP Channel	Metabolic Disease
TRPC5-IN-4 is potent and safe TRPC inhibitor with IC₅₀ value of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5-IN-4 can be used for the research of chronic kidney disease (CKD) .

HY-141411B

(R)-Zevaquenabant (R)-MRI-1867	Drug Isomer Cannabinoid Receptor NO Synthase	Others
(R)-Zevaquenabant ((R)-MRI-1867) is the enantiomer of Zevaquenabant (HY-141411A). Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .

HY-14863

Lunacalcipol CTA-018	VD/VDR Cytochrome P450	Others Endocrinology
Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT) .

HY-109106B

(Rac)-Upacicalcet (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid	CaSR	Endocrinology
(Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-12654R

Molidustat (Standard) BAY 85-3934 (Standard)	HIF/HIF Prolyl-Hydroxylase Reference Standards	Cardiovascular Disease
Molidustat (Standard) is the analytical standard of Molidustat. This product is intended for research and analytical applications. Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-148479

Bixalomer	Biochemical Assay Reagents	Infection
Bixalomer is a phosphate binder. Bixalomer can improve hyperphosphatemia in chronic kidney disease (CKD) rat model. Bixalomer reduces plasma phosphorus level in CKD rat models through binding phosphate in small intestine and reduces phosphate absorption. Bixalomer can be studied in research on hyperphosphatemia .

HY-180108

H111-H7	E1/E2/E3 Enzyme	Endocrinology
H111-H7 is a WW domain containing E3 ubiquitin 27 protein ligase 2 (WWP2) inhibitor with a K_D of 717 nM. H111-H7 inhibits WWP2 expression, restores the succinate dehydrogenase complex subunit C (SDHC) level, and defers the acute kidney injury (AKI)-to-chronic kidney disease (CKD) transition in unilateral kidney ischemia–reperfusion (UIR) mice. H111-H7 can be used for AKI-to-CKD transition research .

HY-180107

H36-E4	E1/E2/E3 Enzyme	Endocrinology
H36-E4 is a WW domain containing E3 ubiquitin 27 protein ligase 2 (WWP2) inhibitor with a K_D of 6.25 μM. H36-E4 inhibits WWP2 expression, restores the succinate dehydrogenase complex subunit C (SDHC) level, and defers the acute kidney injury (AKI)-to-chronic kidney disease (CKD) transition in unilateral kidney ischemia-reperfusion (UIR) mice. H36-E4 can be used for AKI-to-CKD transition research .

HY-P991881

KY1070	TGF-β Receptor Hepcidin Ferroportin	Cardiovascular Disease
KY1070 is a fully human anti-BMP6 antibody with a K_d of 0.00014 μM against the human BMP6. It exhibits high specificity for BMP6, showing no cross-reactivity with other members of the BMP family, and effectively inhibits BMP6-induced BMP receptor heterodimerization and hepcidin expression. KY1070 modulates Ferroportin expression on erythroid progenitor cells and accelerates erythropoiesis. In rodent anemia models, KY1070 reduces the required dose of erythropoietin (EPO) when used in combination with EPO and enhances the responsiveness of mice with chronic kidney disease (CKD)-associated anemia to EPO treatment. KY1070 is applicable for research on anemia of chronic disease ^{[1] [2]}.

HY-159978

EOS789	Sodium Phosphate Cotransporter	Metabolic Disease Inflammation/Immunology
EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC₅₀ values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC₅₀ values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) .

Cat. No.	Product Name

HY-L229

Nephrotoxicity Compound Library	158 compounds
Kidneys are one of the vital organs in the human body. Due to their exposure to higher concentrations of circulating drugs or metabolites, they are highly susceptible to drug-induced renal injury (DIRI). According to statistics, drug-induced kidney injury accounts for approximately 20% of nephrotoxicity reports and can lead to acute kidney injury (AKI), chronic kidney disease (CKD), or even end-stage renal disease (ESRD). Early detection of drug nephrotoxicity is crucial for preventing irreversible kidney damage. Research into its mechanisms can help optimize clinical medication by adjusting dosages or avoiding combinations of nephrotoxic drugs. Additionally, predicting drug-induced nephrotoxicity in early drug development can reduce the risk of late-stage R&D failure. MCE offers 158 nephrotoxicity compounds that have been clearly reported by the FDA to be associated with kidney injury. This library can be used for studying molecular mechanisms of nephrotoxicity or developing novel biomarkers.

Nephrotoxicity Compound Library

158 compounds

Kidneys are one of the vital organs in the human body. Due to their exposure to higher concentrations of circulating drugs or metabolites, they are highly susceptible to drug-induced renal injury (DIRI). According to statistics, drug-induced kidney injury accounts for approximately 20% of nephrotoxicity reports and can lead to acute kidney injury (AKI), chronic kidney disease (CKD), or even end-stage renal disease (ESRD). Early detection of drug nephrotoxicity is crucial for preventing irreversible kidney damage. Research into its mechanisms can help optimize clinical medication by adjusting dosages or avoiding combinations of nephrotoxic drugs. Additionally, predicting drug-induced nephrotoxicity in early drug development can reduce the risk of late-stage R&D failure.

MCE offers 158 nephrotoxicity compounds that have been clearly reported by the FDA to be associated with kidney injury. This library can be used for studying molecular mechanisms of nephrotoxicity or developing novel biomarkers.

Ferric citrate hydrate	Biochemical Assay Reagents
Ferric citrate hydrate, an orally active iron supplement, is an efficacious phosphate binder. Ferric citrate hydrate can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

Cat. No.	Product Name	Target	Research Area